Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Intercept plunges, drags down some NASH peers after CRL from FDA » 07:26
06/29/20
06/29
07:26
06/29/20
07:26
ICPT

Intercept

$77.56 /

-2.09 (-2.62%)

, CBAY

CymaBay

$3.74 /

-0.11 (-2.86%)

, NGM

NGM Biopharmaceuticals

$22.37 /

-0.53 (-2.31%)

, MDGL

Madrigal Pharmaceuticals

$108.04 /

-2.46 (-2.23%)

, NVO

Novo Nordisk

$66.03 /

-1.18 (-1.76%)

, GNFT

Genfit

$5.57 /

-0.42 (-7.01%)

, LLY

Eli Lilly

$162.91 /

-0.09 (-0.06%)

, ALNY

Alnylam

$151.68 /

-4.765 (-3.05%)

Shares of Intercept…

Shares of Intercept Pharmaceuticals (ICPT) have plunged in early morning trading after the company announced that the U.S. Food and Drug Administration has issued a Complete Response Letter regarding the New Drug Application for obeticholic acid for the treatment of fibrosis due to nonalcoholic steatohepatitis, or NASH. Based on the data the FDA has reviewed to date, the Agency has determined that the predicted benefit of OCA based on a surrogate histopathologic endpoint remains uncertain and does not sufficiently outweigh the potential risks to support accelerated approval for the treatment of patients with liver fibrosis due to NASH, Intercept tells investors. Following the announcement, shares of Intercept are down $25.82, or 33%, to $51.67 in pre-market trading. A number of other companies working on NASH treatments are also moving lower, with CymaBay (CBAY) down about 3% and NGM Biopharmaceuticals (NGM) fractionally lower. Other companies exploring NASH treatments include Madrigal Pharmaceuticals (MDGL), Novo Nordisk (NVO), Genfit (GNFT), Eli Lilly (LLY), and Alnylam Pharmaceuticals (ALNY).

ShowHide Related Items >><<
NVO Novo Nordisk
$66.03 /

-1.18 (-1.76%)

NGM NGM Biopharmaceuticals
$22.37 /

-0.53 (-2.31%)

MDGL Madrigal Pharmaceuticals
$108.04 /

-2.46 (-2.23%)

LLY Eli Lilly
$162.91 /

-0.09 (-0.06%)

ICPT Intercept
$77.56 /

-2.09 (-2.62%)

GNFT Genfit
$5.57 /

-0.42 (-7.01%)

CBAY CymaBay
$3.74 /

-0.11 (-2.86%)

ALNY Alnylam
$151.68 /

-4.765 (-3.05%)

ICPT Intercept
$77.56 /

-2.09 (-2.62%)

06/25/20 H.C. Wainwright
Intercept initiated with a Neutral at H.C. Wainwright
06/04/20 BMO Capital
Intercept initiated with an Outperform at BMO Capital
05/22/20 B. Riley FBR
Intercept weakness on 'slight' delay should be bought, says B. Riley FBR
05/22/20 Raymond James
Intercept downgraded at Raymond James after OCA NDA is postponed
CBAY CymaBay
$3.74 /

-0.11 (-2.86%)

06/22/20 B. Riley FBR
CymaBay risk/reward favorable into FDA engagement, says B. Riley FBR
05/26/20 H.C. Wainwright
CymaBay upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Citi
CymaBay price target raised to $7 from $1.60 at Citi
05/12/20 B. Riley FBR
CymaBay upgraded to Buy from Neutral at B. Riley FBR
NGM NGM Biopharmaceuticals
$22.37 /

-0.53 (-2.31%)

06/04/20 BMO Capital
NGM Biopharmaceuticals initiated with an Outperform at BMO Capital
05/06/20 Stifel
Stifel says semaglutide data a 'slight positive' for NGM Biopharmaceuticals
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/31/20 H.C. Wainwright
Akero's BALANCED study results 'quite impressive,' says H.C. Wainwright
MDGL Madrigal Pharmaceuticals
$108.04 /

-2.46 (-2.23%)

06/04/20 BMO Capital
Madrigal Pharmaceuticals initiated with a Market Perform at BMO Capital
05/22/20 B. Riley FBR
Madrigal Pharmaceuticals price target raised to $174 from $134 at B. Riley FBR
05/08/20 H.C. Wainwright
Madrigal Pharmaceuticals price target lowered to $168 from $215 at H.C. Wainwright
05/06/20 Goldman Sachs
Goldman says Novo Nordisk NASH data a 'clear positive' for Intercept
NVO Novo Nordisk
$66.03 /

-1.18 (-1.76%)

06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
05/18/20 Morgan Stanley
Novo Nordisk price target raised to DKK 435 from DKK 425 at Morgan Stanley
05/13/20 JPMorgan
Novo Nordisk price target raised to DKK 480 from DKK 460 at JPMorgan
05/11/20
Fly Intel: Top five analyst downgrades
GNFT Genfit
$5.57 /

-0.42 (-7.01%)

06/25/20 BofA
Genfit's NASH program 'all but done,' says BofA, initiating with an Underperform
06/25/20 BofA
Genfit initiated with an Underperform at BofA
05/13/20 Bryan Garnier
Genfit downgraded to Neutral from Buy at Bryan Garnier
LLY Eli Lilly
$162.91 /

-0.09 (-0.06%)

06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/17/20 JPMorgan
Eli Lilly price target raised to $190 from $175 at JPMorgan
06/16/20
Fly Intel: Top five analyst upgrades
06/16/20 Guggenheim
Guggenheim upgrades Eli Lilly to Buy after 'transformational' breast cancer data
ALNY Alnylam
$151.68 /

-4.765 (-3.05%)

06/08/20 Cantor Fitzgerald
Alnylam lumasiran data reinforces confidence in efficacy, says Cantor Fitzgerald
06/07/20 Stifel
No surprises in 'positive' Alnylan Lumasiran ILLUMINATE-A data, says Stifel
05/12/20 RBC Capital
Alnylam initiated with a Sector Perform at RBC Capital
05/07/20 Oppenheimer
Alnylam price target raised to $162 from $140 at Oppenheimer
NVO Novo Nordisk
$66.03 /

-1.18 (-1.76%)

NGM NGM Biopharmaceuticals
$22.37 /

-0.53 (-2.31%)

MDGL Madrigal Pharmaceuticals
$108.04 /

-2.46 (-2.23%)

LLY Eli Lilly
$162.91 /

-0.09 (-0.06%)

ICPT Intercept
$77.56 /

-2.09 (-2.62%)

CBAY CymaBay
$3.74 /

-0.11 (-2.86%)

ALNY Alnylam
$151.68 /

-4.765 (-3.05%)

  • 11
    Dec
NVO Novo Nordisk
$66.03 /

-1.18 (-1.76%)

LLY Eli Lilly
$162.91 /

-0.09 (-0.06%)

GNFT Genfit
$5.57 /

-0.42 (-7.01%)

ALNY Alnylam
$151.68 /

-4.765 (-3.05%)

NVO Novo Nordisk
$66.03 /

-1.18 (-1.76%)

NGM NGM Biopharmaceuticals
$22.37 /

-0.53 (-2.31%)

LLY Eli Lilly
$162.91 /

-0.09 (-0.06%)

ICPT Intercept
$77.56 /

-2.09 (-2.62%)

CBAY CymaBay
$3.74 /

-0.11 (-2.86%)

NGM NGM Biopharmaceuticals
$22.37 /

-0.53 (-2.31%)

LLY Eli Lilly
$162.91 /

-0.09 (-0.06%)

CBAY CymaBay
$3.74 /

-0.11 (-2.86%)

Over a week ago
Conference/Events
Madrigal Pharmaceuticals management to meet virtually with Oppenheimer » 04:55
06/23/20
06/23
04:55
06/23/20
04:55
MDGL

Madrigal Pharmaceuticals

$111.75 /

-0.55 (-0.49%)

Virtual Meeting to be…

Virtual Meeting to be held on June 23 hosted by Oppenheimer.

ShowHide Related Items >><<
MDGL Madrigal Pharmaceuticals
$111.75 /

-0.55 (-0.49%)

MDGL Madrigal Pharmaceuticals
$111.75 /

-0.55 (-0.49%)

06/04/20 BMO Capital
Madrigal Pharmaceuticals initiated with a Market Perform at BMO Capital
05/22/20 B. Riley FBR
Madrigal Pharmaceuticals price target raised to $174 from $134 at B. Riley FBR
05/08/20 H.C. Wainwright
Madrigal Pharmaceuticals price target lowered to $168 from $215 at H.C. Wainwright
05/06/20 Goldman Sachs
Goldman says Novo Nordisk NASH data a 'clear positive' for Intercept
MDGL Madrigal Pharmaceuticals
$111.75 /

-0.55 (-0.49%)

MDGL Madrigal Pharmaceuticals
$111.75 /

-0.55 (-0.49%)

Conference/Events
Madrigal Pharmaceuticals management to meet virtually with Oppenheimer » 08:19
06/22/20
06/22
08:19
06/22/20
08:19
MDGL

Madrigal Pharmaceuticals

$112.30 /

+1.63 (+1.47%)

Virtual Meeting to be…

Virtual Meeting to be held on June 23 hosted by Oppenheimer.

ShowHide Related Items >><<
MDGL Madrigal Pharmaceuticals
$112.30 /

+1.63 (+1.47%)

MDGL Madrigal Pharmaceuticals
$112.30 /

+1.63 (+1.47%)

06/04/20 BMO Capital
Madrigal Pharmaceuticals initiated with a Market Perform at BMO Capital
05/22/20 B. Riley FBR
Madrigal Pharmaceuticals price target raised to $174 from $134 at B. Riley FBR
05/08/20 H.C. Wainwright
Madrigal Pharmaceuticals price target lowered to $168 from $215 at H.C. Wainwright
05/06/20 Goldman Sachs
Goldman says Novo Nordisk NASH data a 'clear positive' for Intercept
MDGL Madrigal Pharmaceuticals
$112.30 /

+1.63 (+1.47%)

MDGL Madrigal Pharmaceuticals
$112.30 /

+1.63 (+1.47%)

Over a month ago
Initiation
Madrigal Pharmaceuticals initiated with a Market Perform at BMO Capital » 16:14
06/04/20
06/04
16:14
06/04/20
16:14
MDGL

Madrigal Pharmaceuticals

$110.13 /

-0.19 (-0.17%)

BMO Capital analyst…

BMO Capital analyst Matthew Luchini initiated coverage of Madrigal Pharmaceuticals with a Market Perform rating and $135 price target. While positive on lead the company's drug resmetirom and its potential in the nonalcoholic steatohepatitis market, the analyst believes current share levels appropriately reflect the clinical progress made to date. As such, Luchini sees a balanced risk/reward on shares of Madrigal Pharmaceuticals.

ShowHide Related Items >><<
MDGL Madrigal Pharmaceuticals
$110.13 /

-0.19 (-0.17%)

MDGL Madrigal Pharmaceuticals
$110.13 /

-0.19 (-0.17%)

05/22/20 B. Riley FBR
Madrigal Pharmaceuticals price target raised to $174 from $134 at B. Riley FBR
05/08/20 H.C. Wainwright
Madrigal Pharmaceuticals price target lowered to $168 from $215 at H.C. Wainwright
05/06/20 Goldman Sachs
Goldman says Novo Nordisk NASH data a 'clear positive' for Intercept
05/05/20 Chardan
Madrigal Pharmaceuticals initiated with a Buy at Chardan
MDGL Madrigal Pharmaceuticals
$110.13 /

-0.19 (-0.17%)

MDGL Madrigal Pharmaceuticals
$110.13 /

-0.19 (-0.17%)

Conference/Events
Roth Capital biotech analysts to hold an analyst/industry conference call » 14:25
05/26/20
05/26
14:25
05/26/20
14:25
AKRO

Akero Therapeutics

$24.92 /

+0.71 (+2.93%)

, ALT

Altimmune

$8.45 /

+1.51 (+21.76%)

, ENTA

Enanta

$55.90 /

+0.78 (+1.42%)

, GLMD

Galmed

$5.51 /

-0.29 (-5.00%)

, GNFT

Genfit

$5.26 /

+0.02 (+0.38%)

, HEPA

Hepion Pharmaceuticals

$1.94 /

-0.05 (-2.51%)

, ICPT

Intercept

$77.59 /

-2.95 (-3.66%)

, MDGL

Madrigal Pharmaceuticals

$123.16 /

-2.67 (-2.12%)

, NGM

NGM Biopharmaceuticals

$21.22 /

+1.04 (+5.15%)

Biotech Analysts, along…

Biotech Analysts, along with Dr. Eric Lawitz, discuss Non-Alcoholic SteatoHepatitis (NASH) on an Analyst/Industry conference call to be held on May 26 at 3 pm.

ShowHide Related Items >><<
NGM NGM Biopharmaceuticals
$21.22 /

+1.04 (+5.15%)

MDGL Madrigal Pharmaceuticals
$123.16 /

-2.67 (-2.12%)

ICPT Intercept
$77.59 /

-2.95 (-3.66%)

HEPA Hepion Pharmaceuticals
$1.94 /

-0.05 (-2.51%)

GNFT Genfit
$5.26 /

+0.02 (+0.38%)

ENTA Enanta
$55.90 /

+0.78 (+1.42%)

ALT Altimmune
$8.45 /

+1.51 (+21.76%)

AKRO Akero Therapeutics
$24.92 /

+0.71 (+2.93%)

AKRO Akero Therapeutics
$24.92 /

+0.71 (+2.93%)

03/31/20 H.C. Wainwright
Akero's BALANCED study results 'quite impressive,' says H.C. Wainwright
03/02/20 H.C. Wainwright
Akero Therapeutics initiated with a Buy at H.C. Wainwright
02/13/20 Roth Capital
Akero Therapeutics price target raised to $43 from $34 at Roth Capital
02/10/20 Canaccord
Akero Therapeutics initiated with a Buy at Canaccord
ALT Altimmune
$8.45 /

+1.51 (+21.76%)

05/06/20 Roth Capital
Novo data 'sets up the runway' for Altimmune, says Roth Capital
04/01/20
Roth Capital biotech analyst to hold an analyst/industry conference call
02/24/20
Fly Intel: Top five analyst initiations
ENTA Enanta
$55.90 /

+0.78 (+1.42%)

03/17/20 Baird
Baird upgrades 'defensive' Enanta, sees 'real COVID-19 potential'
03/17/20 Baird
Enanta upgraded to Outperform from Neutral at Baird
02/07/20 Roth Capital
Enanta is 'undervalued and underappreciated,' says Roth Capital
11/22/19
Fly Intel: Top five analyst downgrades
GLMD Galmed
$5.51 /

-0.29 (-5.00%)

05/22/20
Fly Intel: Top five analyst downgrades
05/22/20 B. Riley FBR
B. Riley FBR downgrades Galmed, cuts target to $8 from $11
05/22/20 B. Riley FBR
Galmed downgraded to Neutral from Buy at B. Riley FBR
05/15/20 H.C. Wainwright
Galmed price target lowered to $29 from $34 at H.C. Wainwright
GNFT Genfit
$5.26 /

+0.02 (+0.38%)

05/22/20 B. Riley FBR
Madrigal Pharmaceuticals price target raised to $174 from $134 at B. Riley FBR
05/13/20 Bryan Garnier
Genfit downgraded to Neutral from Buy at Bryan Garnier
05/13/20 Kepler Cheuvreux
Genfit downgraded to Reduce from Buy at Kepler Cheuvreux
05/12/20 B. Riley FBR
Genfit downgraded to Neutral from Buy at B. Riley FBR
HEPA Hepion Pharmaceuticals
$1.94 /

-0.05 (-2.51%)

03/20/20 Roth Capital
Roth Capital says Hepion's CRV431 could be used in COVID-19 treatment
11/22/19 Brookline
Hepion Pharmaceuticals initiated with a Buy at Brookline
11/07/19
Fly Intel: Top analyst initiations
11/07/19 Roth Capital
Hepion Pharmaceuticals initiated with a Buy at Roth Capital
ICPT Intercept
$77.59 /

-2.95 (-3.66%)

05/22/20 B. Riley FBR
Intercept weakness on 'slight' delay should be bought, says B. Riley FBR
05/22/20 Raymond James
Intercept downgraded at Raymond James after OCA NDA is postponed
05/22/20 Raymond James
Intercept downgraded to Outperform from Strong Buy at Raymond James
05/22/20 Stifel
Intercept uncertainty, lack of clarity in NASH to hurt sentiment, says Stifel
MDGL Madrigal Pharmaceuticals
$123.16 /

-2.67 (-2.12%)

05/08/20 H.C. Wainwright
Madrigal Pharmaceuticals price target lowered to $168 from $215 at H.C. Wainwright
05/06/20 Goldman Sachs
Goldman says Novo Nordisk NASH data a 'clear positive' for Intercept
05/05/20 Chardan
Madrigal Pharmaceuticals initiated with a Buy at Chardan
NGM NGM Biopharmaceuticals
$21.22 /

+1.04 (+5.15%)

05/06/20 Stifel
Stifel says semaglutide data a 'slight positive' for NGM Biopharmaceuticals
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/27/20 Citi
NGM Biopharmaceuticals price target lowered to $28 from $34 at Citi
NGM NGM Biopharmaceuticals
$21.22 /

+1.04 (+5.15%)

MDGL Madrigal Pharmaceuticals
$123.16 /

-2.67 (-2.12%)

ICPT Intercept
$77.59 /

-2.95 (-3.66%)

GLMD Galmed
$5.51 /

-0.29 (-5.00%)

ENTA Enanta
$55.90 /

+0.78 (+1.42%)

ALT Altimmune
$8.45 /

+1.51 (+21.76%)

AKRO Akero Therapeutics
$24.92 /

+0.71 (+2.93%)

ICPT Intercept
$77.59 /

-2.95 (-3.66%)

GNFT Genfit
$5.26 /

+0.02 (+0.38%)

NGM NGM Biopharmaceuticals
$21.22 /

+1.04 (+5.15%)

MDGL Madrigal Pharmaceuticals
$123.16 /

-2.67 (-2.12%)

ICPT Intercept
$77.59 /

-2.95 (-3.66%)

GNFT Genfit
$5.26 /

+0.02 (+0.38%)

ALT Altimmune
$8.45 /

+1.51 (+21.76%)

AKRO Akero Therapeutics
$24.92 /

+0.71 (+2.93%)

NGM NGM Biopharmaceuticals
$21.22 /

+1.04 (+5.15%)

ICPT Intercept
$77.59 /

-2.95 (-3.66%)

ALT Altimmune
$8.45 /

+1.51 (+21.76%)

AKRO Akero Therapeutics
$24.92 /

+0.71 (+2.93%)

Conference/Events
Roth Capital biotech analysts to hold an analyst/industry conference call » 09:42
05/26/20
05/26
09:42
05/26/20
09:42
AKRO

Akero Therapeutics

$24.21 /

+ (+0.00%)

, ALT

Altimmune

$6.94 /

+ (+0.00%)

, ENTA

Enanta

$55.12 /

+ (+0.00%)

, GLMD

Galmed

$5.80 /

+ (+0.00%)

, GNFT

Genfit

$5.24 /

+ (+0.00%)

, HEPA

Hepion Pharmaceuticals

$1.99 /

+ (+0.00%)

, ICPT

Intercept

$80.54 /

+ (+0.00%)

, MDGL

Madrigal Pharmaceuticals

$125.83 /

+ (+0.00%)

, NGM

NGM Biopharmaceuticals

$20.18 /

+ (+0.00%)

Biotech Analysts, along…

Biotech Analysts, along with Dr. Eric Lawitz, discuss Non-Alcoholic SteatoHepatitis (NASH) on an Analyst/Industry conference call to be held on May 26 at 3 pm.

ShowHide Related Items >><<
NGM NGM Biopharmaceuticals
$20.18 /

+ (+0.00%)

MDGL Madrigal Pharmaceuticals
$125.83 /

+ (+0.00%)

ICPT Intercept
$80.54 /

+ (+0.00%)

HEPA Hepion Pharmaceuticals
$1.99 /

+ (+0.00%)

GNFT Genfit
$5.24 /

+ (+0.00%)

ENTA Enanta
$55.12 /

+ (+0.00%)

ALT Altimmune
$6.94 /

+ (+0.00%)

AKRO Akero Therapeutics
$24.21 /

+ (+0.00%)

AKRO Akero Therapeutics
$24.21 /

+ (+0.00%)

03/31/20 H.C. Wainwright
Akero's BALANCED study results 'quite impressive,' says H.C. Wainwright
03/02/20 H.C. Wainwright
Akero Therapeutics initiated with a Buy at H.C. Wainwright
02/13/20 Roth Capital
Akero Therapeutics price target raised to $43 from $34 at Roth Capital
02/10/20 Canaccord
Akero Therapeutics initiated with a Buy at Canaccord
ALT Altimmune
$6.94 /

+ (+0.00%)

05/06/20 Roth Capital
Novo data 'sets up the runway' for Altimmune, says Roth Capital
04/01/20
Roth Capital biotech analyst to hold an analyst/industry conference call
02/24/20
Fly Intel: Top five analyst initiations
ENTA Enanta
$55.12 /

+ (+0.00%)

03/17/20 Baird
Baird upgrades 'defensive' Enanta, sees 'real COVID-19 potential'
03/17/20 Baird
Enanta upgraded to Outperform from Neutral at Baird
02/07/20 Roth Capital
Enanta is 'undervalued and underappreciated,' says Roth Capital
11/22/19
Fly Intel: Top five analyst downgrades
GLMD Galmed
$5.80 /

+ (+0.00%)

05/22/20
Fly Intel: Top five analyst downgrades
05/22/20 B. Riley FBR
B. Riley FBR downgrades Galmed, cuts target to $8 from $11
05/22/20 B. Riley FBR
Galmed downgraded to Neutral from Buy at B. Riley FBR
05/15/20 H.C. Wainwright
Galmed price target lowered to $29 from $34 at H.C. Wainwright
GNFT Genfit
$5.24 /

+ (+0.00%)

05/22/20 B. Riley FBR
Madrigal Pharmaceuticals price target raised to $174 from $134 at B. Riley FBR
05/13/20 Bryan Garnier
Genfit downgraded to Neutral from Buy at Bryan Garnier
05/13/20 Kepler Cheuvreux
Genfit downgraded to Reduce from Buy at Kepler Cheuvreux
05/12/20 B. Riley FBR
Genfit downgraded to Neutral from Buy at B. Riley FBR
HEPA Hepion Pharmaceuticals
$1.99 /

+ (+0.00%)

03/20/20 Roth Capital
Roth Capital says Hepion's CRV431 could be used in COVID-19 treatment
11/22/19 Brookline
Hepion Pharmaceuticals initiated with a Buy at Brookline
11/07/19
Fly Intel: Top analyst initiations
11/07/19 Roth Capital
Hepion Pharmaceuticals initiated with a Buy at Roth Capital
ICPT Intercept
$80.54 /

+ (+0.00%)

05/22/20 B. Riley FBR
Intercept weakness on 'slight' delay should be bought, says B. Riley FBR
05/22/20 Raymond James
Intercept downgraded at Raymond James after OCA NDA is postponed
05/22/20 Raymond James
Intercept downgraded to Outperform from Strong Buy at Raymond James
05/22/20 Stifel
Intercept uncertainty, lack of clarity in NASH to hurt sentiment, says Stifel
MDGL Madrigal Pharmaceuticals
$125.83 /

+ (+0.00%)

05/08/20 H.C. Wainwright
Madrigal Pharmaceuticals price target lowered to $168 from $215 at H.C. Wainwright
05/06/20 Goldman Sachs
Goldman says Novo Nordisk NASH data a 'clear positive' for Intercept
05/05/20 Chardan
Madrigal Pharmaceuticals initiated with a Buy at Chardan
NGM NGM Biopharmaceuticals
$20.18 /

+ (+0.00%)

05/06/20 Stifel
Stifel says semaglutide data a 'slight positive' for NGM Biopharmaceuticals
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/27/20 Citi
NGM Biopharmaceuticals price target lowered to $28 from $34 at Citi
NGM NGM Biopharmaceuticals
$20.18 /

+ (+0.00%)

MDGL Madrigal Pharmaceuticals
$125.83 /

+ (+0.00%)

ICPT Intercept
$80.54 /

+ (+0.00%)

GLMD Galmed
$5.80 /

+ (+0.00%)

ENTA Enanta
$55.12 /

+ (+0.00%)

ALT Altimmune
$6.94 /

+ (+0.00%)

AKRO Akero Therapeutics
$24.21 /

+ (+0.00%)

ICPT Intercept
$80.54 /

+ (+0.00%)

GNFT Genfit
$5.24 /

+ (+0.00%)

NGM NGM Biopharmaceuticals
$20.18 /

+ (+0.00%)

MDGL Madrigal Pharmaceuticals
$125.83 /

+ (+0.00%)

ICPT Intercept
$80.54 /

+ (+0.00%)

GNFT Genfit
$5.24 /

+ (+0.00%)

ALT Altimmune
$6.94 /

+ (+0.00%)

AKRO Akero Therapeutics
$24.21 /

+ (+0.00%)

NGM NGM Biopharmaceuticals
$20.18 /

+ (+0.00%)

ICPT Intercept
$80.54 /

+ (+0.00%)

ALT Altimmune
$6.94 /

+ (+0.00%)

AKRO Akero Therapeutics
$24.21 /

+ (+0.00%)

Recommendations
Madrigal Pharmaceuticals price target raised to $174 from $134 at B. Riley FBR » 08:54
05/22/20
05/22
08:54
05/22/20
08:54
MDGL

Madrigal Pharmaceuticals

$119.46 /

-2.52 (-2.07%)

, GNFT

Genfit

$5.26 /

-0.16 (-2.95%)

B. Riley FBR analyst…

B. Riley FBR analyst Mayank Mamtani raised the firm's price target on Madrigal Pharmaceuticals (MDGL) to $174 from $134 and keeps a Buy rating on the shares. After hosting a call with Dr. Stephen Harrison from Pinnacle Clinical Research on recent advances in clinical development of therapeutics in non-alcoholic steatohepatitis, the analyst believes the high placebo response in Genfit's (GNFT) Phase III trial is bullish for Madrigal.

ShowHide Related Items >><<
MDGL Madrigal Pharmaceuticals
$119.46 /

-2.52 (-2.07%)

GNFT Genfit
$5.26 /

-0.16 (-2.95%)

MDGL Madrigal Pharmaceuticals
$119.46 /

-2.52 (-2.07%)

05/08/20 H.C. Wainwright
Madrigal Pharmaceuticals price target lowered to $168 from $215 at H.C. Wainwright
05/06/20 Goldman Sachs
Goldman says Novo Nordisk NASH data a 'clear positive' for Intercept
05/05/20 Chardan
Madrigal Pharmaceuticals initiated with a Buy at Chardan
03/31/20 H.C. Wainwright
Akero's BALANCED study results 'quite impressive,' says H.C. Wainwright
GNFT Genfit
$5.26 /

-0.16 (-2.95%)

05/13/20 Bryan Garnier
Genfit downgraded to Neutral from Buy at Bryan Garnier
05/13/20 Kepler Cheuvreux
Genfit downgraded to Reduce from Buy at Kepler Cheuvreux
05/12/20 B. Riley FBR
Genfit downgraded to Neutral from Buy at B. Riley FBR
05/12/20 Roth Capital
Genfit price target lowered to EUR 13 from EUR 70 at Roth Capital
MDGL Madrigal Pharmaceuticals
$119.46 /

-2.52 (-2.07%)

GNFT Genfit
$5.26 /

-0.16 (-2.95%)

MDGL Madrigal Pharmaceuticals
$119.46 /

-2.52 (-2.07%)

GNFT Genfit
$5.26 /

-0.16 (-2.95%)

Recommendations
Madrigal Pharmaceuticals price target lowered to $168 from $215 at H.C. Wainwright » 07:37
05/08/20
05/08
07:37
05/08/20
07:37
MDGL

Madrigal Pharmaceuticals

$88.49 /

+0.13 (+0.15%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Ed Arce lowered the firm's price target on Madrigal Pharmaceuticals to $168 from $215 and keeps a Buy rating on the shares following the company's Q1 results.

ShowHide Related Items >><<
MDGL Madrigal Pharmaceuticals
$88.49 /

+0.13 (+0.15%)

05/06/20 Goldman Sachs
Goldman says Novo Nordisk NASH data a 'clear positive' for Intercept
05/05/20 Chardan
Madrigal Pharmaceuticals initiated with a Buy at Chardan
03/31/20 H.C. Wainwright
Akero's BALANCED study results 'quite impressive,' says H.C. Wainwright
03/05/20 Citi
Madrigal Pharmaceuticals price target lowered to $155 from $166 at Citi
Earnings
Madrigal Pharmaceuticals reports Q1 EPS ($2.34), consensus ($1.94) » 07:34
05/07/20
05/07
07:34
05/07/20
07:34
MDGL

Madrigal Pharmaceuticals

$88.36 /

-0.19 (-0.21%)

"Madrigal continued…

"Madrigal continued to make progress toward our clinical development and business objectives during Q1, despite challenges associated with the COVID-19 pandemic. Importantly, we continued to screen and enroll patients in our Phase 3 studies, MAESTRO-NASH and MAESTRO-NAFLD-1," stated CEO Paul Friedman. "We are also pleased that Remy Sukhija has joined Madrigal as Senior Vice President and Chief Commercial Officer". As of March 31, Madrigal had cash, cash equivalents and marketable securities of $408.5M, compared to $439.0M at December 31, 2019. The decrease in cash and marketable securities resulted primarily from cash used in operations of $30.5M.

ShowHide Related Items >><<
MDGL Madrigal Pharmaceuticals
$88.36 /

-0.19 (-0.21%)

05/06/20 Goldman Sachs
Goldman says Novo Nordisk NASH data a 'clear positive' for Intercept
05/05/20 Chardan
Madrigal Pharmaceuticals initiated with a Buy at Chardan
03/31/20 H.C. Wainwright
Akero's BALANCED study results 'quite impressive,' says H.C. Wainwright
03/05/20 Citi
Madrigal Pharmaceuticals price target lowered to $155 from $166 at Citi
On The Fly
Novo Nordisk slips as analysts discuss NASH data, read-through to peers » 14:46
05/06/20
05/06
14:46
05/06/20
14:46
NVO

Novo Nordisk

$62.47 /

-0.81 (-1.28%)

, ICPT

Intercept

$89.74 /

+9.16 (+11.37%)

, NGM

NGM Biopharmaceuticals

$19.99 /

+2.06 (+11.49%)

, GNFT

Genfit

$21.09 /

-0.85 (-3.87%)

, ALT

Altimmune

$3.02 /

-0.11 (-3.51%)

, AKRO

Akero Therapeutics

$20.95 /

+0.27 (+1.31%)

, BMY

Bristol-Myers

$61.48 /

+0.13 (+0.21%)

, MDGL

Madrigal Pharmaceuticals

$88.54 /

-0.01 (-0.01%)

, VKTX

Viking Therapeutics

$6.64 /

-0.05 (-0.75%)

In conjunction with the…

Open Full Text

ShowHide Related Items >><<
NVO Novo Nordisk
$62.47 /

-0.81 (-1.28%)

05/06/20 Goldman Sachs
Goldman says Novo Nordisk NASH data a 'clear positive' for Intercept
05/06/20 Roth Capital
Novo data 'sets up the runway' for Altimmune, says Roth Capital
05/06/20 Stifel
Stifel says semaglutide data a 'slight positive' for NGM Biopharmaceuticals
05/04/20
Fly Intel: Top five analyst initiations
ICPT Intercept
$89.74 /

+9.16 (+11.37%)

04/02/20 Chardan
Intercept initiated with a Buy at Chardan
03/19/20 JMP Securities
JMP Securities says report on Intercept's OCA 'favorable'
NGM NGM Biopharmaceuticals
$19.99 /

+2.06 (+11.49%)

04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/31/20 H.C. Wainwright
Akero's BALANCED study results 'quite impressive,' says H.C. Wainwright
03/27/20 Citi
NGM Biopharmaceuticals price target lowered to $28 from $34 at Citi
GNFT Genfit
$21.09 /

-0.85 (-3.87%)

04/09/20 H.C. Wainwright
Genfit price target lowered to $46 from $58 at H.C. Wainwright
01/23/20 B. Riley FBR
Genfit selloff on data speculation unwarranted, says B. Riley FBR
ALT Altimmune
$3.02 /

-0.11 (-3.51%)

04/01/20
Roth Capital biotech analyst to hold an analyst/industry conference call
02/24/20
Fly Intel: Top five analyst initiations
AKRO Akero Therapeutics
$20.95 /

+0.27 (+1.31%)

03/02/20 H.C. Wainwright
Akero Therapeutics initiated with a Buy at H.C. Wainwright
02/13/20 Roth Capital
Akero Therapeutics price target raised to $43 from $34 at Roth Capital
02/10/20 Canaccord
Akero Therapeutics initiated with a Buy at Canaccord
BMY Bristol-Myers
$61.48 /

+0.13 (+0.21%)

04/20/20 Piper Sandler
Exelixis combo approval would increase kidney cancer use, says Piper Sandler
04/02/20
Fly Intel: Top five analyst upgrades
04/02/20 Morgan Stanley
Bristol-Myers upgraded to Overweight after pullback at Morgan Stanley
04/02/20 Morgan Stanley
Bristol-Myers upgraded to Overweight from Equal Weight at Morgan Stanley
MDGL Madrigal Pharmaceuticals
$88.54 /

-0.01 (-0.01%)

05/05/20 Chardan
Madrigal Pharmaceuticals initiated with a Buy at Chardan
03/05/20 Citi
Madrigal Pharmaceuticals price target lowered to $155 from $166 at Citi
VKTX Viking Therapeutics
$6.64 /

-0.05 (-0.75%)

05/05/20 Chardan
Viking Therapeutics initiated with a Buy at Chardan
05/04/20 B. Riley FBR
Viking Therapeutics price target lowered to $12 from $16 at B. Riley FBR
05/01/20 BTIG
Viking Therapeutics initiated with a Buy at BTIG
02/27/20 H.C. Wainwright
Viking Therapeutics price target lowered to $18 from $31 at H.C. Wainwright

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.